基于68Ga的放射性药物：生产与应用的关系。
68Ga-Based radiopharmaceuticals: production and application relationship.
作者信息
Velikyan Irina
机构信息
Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala SE-751 85, Sweden.
PET Center, Center for Medical Imaging, Uppsala University Hospital, Uppsala SE-751 85, Sweden .
出版信息
Molecules. 2015 Jul 16;20(7):12913-43. doi: 10.3390/molecules200712913.
The contribution of 68Ga to the promotion and expansion of clinical research and routine positron emission tomography (PET) for earlier better diagnostics and individualized medicine is considerable. The potential applications of 68Ga-comprising imaging agents include targeted, pre-targeted and non-targeted imaging. This review discusses the key aspects of the production of 68Ga and 68Ga-based radiopharmaceuticals in the light of the impact of regulatory requirements and endpoint pre-clinical and clinical applications.
68Ga对促进和扩展临床研究以及用于早期更好诊断和个性化医疗的常规正电子发射断层扫描（PET）的贡献相当大。含68Ga的显像剂的潜在应用包括靶向成像、预靶向成像和非靶向成像。本综述根据监管要求以及临床前和临床应用终点的影响，讨论了68Ga和基于68Ga的放射性药物生产的关键方面。
Zotero 插件